Gyre Therapeutics (NASDAQ:GYRE) Shares Up 2.4% – Time to Buy?

Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) shot up 2.4% during trading on Tuesday . The stock traded as high as $8.09 and last traded at $8.09. 53,681 shares traded hands during mid-day trading, a decline of 25% from the average session volume of 71,135 shares. The stock had previously closed at $7.90.

Wall Street Analyst Weigh In

GYRE has been the subject of a number of research reports. Wall Street Zen upgraded shares of Gyre Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 15th. Zacks Research upgraded Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, November 14th. Jefferies Financial Group began coverage on Gyre Therapeutics in a report on Friday, October 10th. They issued a “buy” rating and a $16.00 price objective for the company. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Gyre Therapeutics in a research note on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $17.00.

Gyre Therapeutics Price Performance

The business’s fifty day simple moving average is $7.61 and its two-hundred day simple moving average is $7.65. The company has a market cap of $779.31 million, a PE ratio of 269.76 and a beta of 1.99.

Hedge Funds Weigh In On Gyre Therapeutics

Hedge funds have recently bought and sold shares of the business. State of Alaska Department of Revenue acquired a new stake in Gyre Therapeutics in the third quarter valued at approximately $38,000. Bank of America Corp DE lifted its position in shares of Gyre Therapeutics by 28.8% during the 2nd quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock valued at $46,000 after buying an additional 1,402 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Gyre Therapeutics by 84.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock valued at $47,000 after acquiring an additional 2,961 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Gyre Therapeutics by 77.8% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock valued at $54,000 after acquiring an additional 3,244 shares during the period. Finally, Lazard Asset Management LLC purchased a new stake in Gyre Therapeutics in the 3rd quarter worth $111,000. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.